News

10 million Euros to keep moving
Enlarge image

BusinessNetherlandsUK

10 million Euros to keep moving

21.11.2012 - The Dutch biotech company Kiadis BV has raised €10m in a financing round led by its largest investor.

This round was led by the Company’s largest shareholder Life Sciences Partners and supported by a large investment from DFJ-Esprit, a tech investor based in London. Other financiers included Alta Partners (San Francisco), Quest for Growth (Netherlands) and NOM, the regional development for Northern Netherlands. Kiadis Pharma is specialised on developing treatments for blood cancer and related diseases.

The company's most advanced project is ATIR, which focuses on donor immune cells in which the alloreactive T-cells that would otherwise attack the patient’s body have been selectively eliminated. The cells are infused in the patient about 30 days after the patient has undergone a stem cell transplantation in which all immune cells have been depleted from the graft of the donor. 

The financing will enable Kiadis Pharma to perform a confirmatory multi-centre Phase II proof-of-concept study with its lead product and to prepare a pivotal Phase II/III study. Manfred Ruediger, CEO of Kiadis Pharma and Venture Partner at Kiadis shareholder LSP, commented: “We are delighted with the enthusiastic support from existing and new investors, which attests to the exciting clinical data generated for ATIR so far and to the progress the company has achieved over the last year. We are determined to advance ATIR in close cooperation with our clinical investigators in North America and Europe.” Kiadis Pharma merged in 2007 with the Canadian Biotech Celmed Biosciences.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/10-million-euros-to-keep-moving.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2296.2%
  • TRANSGENE (F)5.08 EUR77.0%
  • BIOTECH PHARMACON (N)12.60 NOK33.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.90 EUR-42.5%
  • BIONOR PHARMA (N)1.28 NOK-37.6%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 30.08.2015